
    
      This study will be conducted at a single site as a double-blind, placebo-controlled, mulitple
      ascending oral doses evaluation of the safety, tolerability, and pharmacokinetics of DSP-1053
      and its metabolites in healthy subjects with Major depressive disorder after the minimumally
      intolerated dose is reached in healthy subjects
    
  